Astrazeneca and Serum Institute Agreement
AstraZeneca and Serum Institute Reach Agreement for COVID-19 Vaccine Production
In a significant development in the fight against COVID-19, AstraZeneca has reportedly reached an agreement with Serum Institute of India to produce and supply its COVID-19 vaccine candidate to low and middle-income countries.
AstraZeneca`s vaccine, developed in collaboration with the University of Oxford, is among the leading COVID-19 vaccine candidates currently being developed worldwide. The vaccine has shown promising results in clinical trials so far, and AstraZeneca has already signed agreements with several governments to supply it once it is approved for use.
Under the newly announced agreement, Serum Institute of India, the world`s largest vaccine manufacturer by volume, will produce and supply AstraZeneca`s vaccine to around 92 countries, including India, which has been hit hard by the COVID-19 pandemic. The agreement seeks to ensure that the vaccine is available to all, regardless of their ability to pay.
The deal is a significant milestone for AstraZeneca, which has pledged to provide access to its vaccine on a not-for-profit basis during the pandemic. AstraZeneca said that the collaboration with Serum Institute of India would help it scale up production and supply of the vaccine at an unprecedented pace.
For Serum Institute of India, the agreement is an opportunity to play a vital role in the global response to COVID-19. The company has already begun manufacturing the vaccine candidate, and it expects to produce up to 100 million doses by the end of 2020. The company has also reportedly agreed to provide up to 1 billion doses of the vaccine to low and middle-income countries during the pandemic.
The agreement between AstraZeneca and Serum Institute of India highlights the importance of international collaboration in the fight against COVID-19. With the pandemic affecting people worldwide, it is crucial that all countries have access to vaccines and treatments to ensure that the virus can be effectively managed.
In conclusion, the agreement between AstraZeneca and Serum Institute of India is a significant step forward in the fight against COVID-19. It demonstrates the importance of collaboration and access to vaccines for all, regardless of their location or income level. With the vaccine expected to be available soon, we can hope that the pandemic can be brought under control, and life can return to normalcy.